Cargando…

Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa

Resistance development and exhaustion of the arsenal of existing antibacterial agents urgently require an alternative approach toward drug discovery. Herein, we report the screening of Medicines for Malaria Venture (MMV) Pandemic Response Box (PRB) through a cascade developed to streamline the poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Macho, Markéta, Saha, Subhasish, Konert, Grzegorz, Banerjee, Avik, Ewe, Daniela, Hrouzek, Pavel, Urajová, Petra, Saurav, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769688/
https://www.ncbi.nlm.nih.gov/pubmed/36301146
http://dx.doi.org/10.1128/spectrum.02232-22
_version_ 1784854425868697600
author Macho, Markéta
Saha, Subhasish
Konert, Grzegorz
Banerjee, Avik
Ewe, Daniela
Hrouzek, Pavel
Urajová, Petra
Saurav, Kumar
author_facet Macho, Markéta
Saha, Subhasish
Konert, Grzegorz
Banerjee, Avik
Ewe, Daniela
Hrouzek, Pavel
Urajová, Petra
Saurav, Kumar
author_sort Macho, Markéta
collection PubMed
description Resistance development and exhaustion of the arsenal of existing antibacterial agents urgently require an alternative approach toward drug discovery. Herein, we report the screening of Medicines for Malaria Venture (MMV) Pandemic Response Box (PRB) through a cascade developed to streamline the potential compounds with antivirulent properties to combat an opportunistic pathogen, Pseudomonas aeruginosa. To find an agent suppressing the production of P. aeruginosa virulence factors, we assessed the potential of the compounds in PRB with quorum sensing inhibitory activity. Our approach led us to identify four compounds with significant inhibition of extracellular virulence factor production and biofilm formation. This provides an opportunity to expand and redirect the application of these data sets toward the development of a drug with unexplored target-based activity. IMPORTANCE The rise of drug-resistant pathogens as well as overuse and misuse of antibiotics threatens modern medicine as the number of effective antimicrobial drugs steadily decreases. Given the nature of antimicrobial resistance development under intense selective pressure such as the one posed by pathogen-eliminating antibiotics, new treatment options which could slow down the emergence of resistance are urgently needed. Antivirulence therapy aims at suppressing a pathogen’s ability to cause disease rather than eliminating it, generating significantly lower selective pressure. Quorum sensing inhibitors are thought to be able to downregulate the production of virulence factors, allowing for smaller amounts of antimicrobials to be used and thus preventing the emergence of resistance. The PRB constitutes an unprecedented opportunity to repurpose new as well as known compounds with cytotoxicity and in vitro absorption, distribution, metabolism and excretion (ADME) profile available, thus shortening the time between compound discovery and medicinal use.
format Online
Article
Text
id pubmed-9769688
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-97696882022-12-22 Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa Macho, Markéta Saha, Subhasish Konert, Grzegorz Banerjee, Avik Ewe, Daniela Hrouzek, Pavel Urajová, Petra Saurav, Kumar Microbiol Spectr Observation Resistance development and exhaustion of the arsenal of existing antibacterial agents urgently require an alternative approach toward drug discovery. Herein, we report the screening of Medicines for Malaria Venture (MMV) Pandemic Response Box (PRB) through a cascade developed to streamline the potential compounds with antivirulent properties to combat an opportunistic pathogen, Pseudomonas aeruginosa. To find an agent suppressing the production of P. aeruginosa virulence factors, we assessed the potential of the compounds in PRB with quorum sensing inhibitory activity. Our approach led us to identify four compounds with significant inhibition of extracellular virulence factor production and biofilm formation. This provides an opportunity to expand and redirect the application of these data sets toward the development of a drug with unexplored target-based activity. IMPORTANCE The rise of drug-resistant pathogens as well as overuse and misuse of antibiotics threatens modern medicine as the number of effective antimicrobial drugs steadily decreases. Given the nature of antimicrobial resistance development under intense selective pressure such as the one posed by pathogen-eliminating antibiotics, new treatment options which could slow down the emergence of resistance are urgently needed. Antivirulence therapy aims at suppressing a pathogen’s ability to cause disease rather than eliminating it, generating significantly lower selective pressure. Quorum sensing inhibitors are thought to be able to downregulate the production of virulence factors, allowing for smaller amounts of antimicrobials to be used and thus preventing the emergence of resistance. The PRB constitutes an unprecedented opportunity to repurpose new as well as known compounds with cytotoxicity and in vitro absorption, distribution, metabolism and excretion (ADME) profile available, thus shortening the time between compound discovery and medicinal use. American Society for Microbiology 2022-10-27 /pmc/articles/PMC9769688/ /pubmed/36301146 http://dx.doi.org/10.1128/spectrum.02232-22 Text en Copyright © 2022 Macho et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Observation
Macho, Markéta
Saha, Subhasish
Konert, Grzegorz
Banerjee, Avik
Ewe, Daniela
Hrouzek, Pavel
Urajová, Petra
Saurav, Kumar
Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
title Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
title_full Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
title_fullStr Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
title_full_unstemmed Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
title_short Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
title_sort screening of the medicines for malaria venture pandemic response box for discovery of antivirulent drug against pseudomonas aeruginosa
topic Observation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769688/
https://www.ncbi.nlm.nih.gov/pubmed/36301146
http://dx.doi.org/10.1128/spectrum.02232-22
work_keys_str_mv AT machomarketa screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa
AT sahasubhasish screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa
AT konertgrzegorz screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa
AT banerjeeavik screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa
AT ewedaniela screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa
AT hrouzekpavel screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa
AT urajovapetra screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa
AT sauravkumar screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa